Drug intelligence / Profile preview

heat-killed bifidobacterium bifidum CBT-BF3

Development stage: Preclinical
Lead developer: Korea Food Research Institute
Modality: Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
Administration: Oral

Overview

Heat-killed Bifidobacterium bifidum CBT-BF3 is a postbiotic (paraprobiotic) preparation developed by Cell Biotech Co. Ltd. derived from the probiotic strain Bifidobacterium bifidum CBT-BF3 (KCTC 12199BP). The preparation involves heat-treating the live bacteria at 121°C for 20 minutes to inactivate the cells while retaining biological activity. It is primarily investigated for the treatment of atopic dermatitis by modulating the gut-skin axis. Its mechanism involves regulating immune responses, specifically by decreasing the expression of Th2 and Th17 cell transcription factors and cytokines while increasing regulatory T cell (Treg) markers, thereby suppressing allergic inflammation.

Other names: heat-killed Bifidobacterium bifidum CBT-BF3paraprobiotic CBT-BF3postbiotic CBT-BF3heat-inactivated Bifidobacterium bifidum CBT-BF3

Beyond the preview

Go deeper on heat-killed bifidobacterium bifidum CBT-BF3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on heat-killed bifidobacterium bifidum CBT-BF3.

Explore the full profile